HTA Evolution & Digital Health

MarcusWelcome to the Access Brief — your daily briefing on what's moving in HEOR, HTA, and market access. I'm Marcus, and it's great to have you with us today.

SaraAnd I'm Sara. Always good to be here — and I'll say, today's topics feel particularly timely given the shifting evidentiary landscape.

MarcusSame here. We're looking at CMS Part D redesign implementation hurdles — the operational friction points are becoming clearer. Then ICER's framework evolution for ultra-orphan therapies — the value assessment paradigm is shifting. Plus FDA guidance on decentralized trials — this could reshape clinical evidence generation. And NICE's RWE integration push — the methodological frontier is moving fast.

SaraThat second one catches my eye — the ultra-orphan framework question is one where payer perspectives on long-term value remain unresolved.

MarcusExactly. Let's get into it.

MarcusStarting with CMS Part D redesign implementation. The operational hurdles are becoming apparent as the rollout progresses. We're seeing significant friction around patient cost-sharing models and formulary management complexities.

SaraWhat's striking here is the disconnect between policy intent and real-world execution. Payers are struggling with the transition timelines, especially for vulnerable populations where benefit design changes create access risks.

MarcusThat connects to something I keep coming back to — the gap between regulatory timelines and operational capacity. The CMS infrastructure wasn't built for this level of real-time adjustment.

SaraThe part that gives me pause is the rebate clawback mechanics. They're creating perverse incentives for plan sponsors that could undermine the program's equity goals.

MarcusI wonder if that's the full picture though... From the industry side, the predictability of the model is actually improving long-term planning for evidence generation. It's forcing earlier engagement with HTA bodies.

SaraThat's one read — I'd frame it slightly differently. The operational chaos is creating evidentiary uncertainty, which ultimately delays patient access. The system needs more runway.

MarcusFair point. The tension between innovation and system sustainability is real here.

SaraShifting to ICER's ultra-orphan framework evolution. The new emphasis on long-term value and disease modification is significant, but the methodology for capturing that remains underdeveloped.

MarcusWhat strikes me is how this reflects broader HEOR trends toward real-world evidence. ICER is pushing for more natural history data to contextualize ultra-orphan outcomes.

SaraExactly, and from the payer side, the budget impact question for these therapies hasn't fundamentally changed. We still face the same opportunity cost dilemmas regardless of value framing.

MarcusThe methodological evolution is necessary though. Traditional cost-effectiveness models fail to capture the societal value of ultra-rare disease treatments adequately.

SaraThat's fair, though I think payers would see differently when faced with 7-figure price tags. The evidence threshold hasn't meaningfully shifted in practice.

MarcusThe precedent set here could redefine how we approach value in ultra-orphan spaces. It's one of those stories where the methodology is racing to catch up to clinical reality.

SaraWe'll need to watch how this plays out in upcoming assessments.

MarcusNow to FDA guidance on decentralized trials. The new framework emphasizes flexible evidence generation but creates compliance complexities for sponsors.

SaraWhat's interesting is how this intersects with HTA evidence requirements. Decentralized data often lacks the standardization that HTA bodies demand for cross-jurisdictional submissions.

MarcusThat's precisely the tension — the push for pragmatic trials versus HTA's need for controlled comparators. The FDA guidance doesn't address HTA acceptance directly.

SaraThe part that gives me pause is data governance. How do we ensure real-world data from decentralized trials meets HTA quality standards? The infrastructure gap is significant.

MarcusI'd push back slightly on that... This could actually accelerate RWE integration in HTA by generating more context-rich data. The key is methodological harmonization.

SaraBut the timeline mismatch remains. FDA approval and HTA appraisal often operate on different schedules, creating evidence fragmentation.

MarcusThat connects to something I keep coming back to — the need for parallel regulatory-HTA pathways. This guidance is a step in that direction.

SaraWe'll see how it plays out in practice.

SaraFinally, NICE's RWE integration push. The updated guidance emphasizes real-world data as complementary evidence, not just post-marketing surveillance.

MarcusWhat's significant here is the shift from supplemental to primary evidence streams. NICE is increasingly accepting RWE for technology appraisals in specific contexts.

SaraExactly, and from the payer perspective, this addresses a critical gap — the lack of long-term real-world data for novel mechanisms. But the methodological rigor required remains a hurdle.

MarcusThe precedent set with cancer therapies is expanding to other areas. We're seeing more RWE-based submissions for rare diseases where traditional trials aren't feasible.

SaraThat's one read — I'd frame it slightly differently. The resource intensity of generating RWE that meets NICE's standards is substantial, creating access delays for smaller companies.

MarcusThe operational challenges are real, but the direction is clear. RWE is becoming central to evidence generation, not an afterthought.

SaraWe'll need to watch how the methodology evolves to ensure equity in access.

SaraA lot to think about today. I'll be watching how the CMS Part D implementation impacts evidence generation timelines for new therapies.

MarcusSame — and for me the thread running through today is the growing disconnect between regulatory flexibility and HTA methodological conservatism. Worth sitting with.

SaraThanks so much for listening — really glad you're here with us.

MarcusWe'll be back tomorrow. Show notes and transcripts at outcomes-analytica.no. See you then.

SaraThanks for listening — see you tomorrow.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.